• Publications
  • Influence
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
TLDR
The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. Expand
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified. Expand
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
TLDR
The recent emergence of new SARS-CoV-2 variants B.1.2.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines. Expand
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
TLDR
Preference-specific antibodies that were substantially more potent than the prophylactic antibody palivizumab were identified, which should enable design of improved vaccine antigens and define new targets for passive prevention of RSV-induced disease. Expand
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine. Expand
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
TLDR
An engineering strategy for stabilization of soluble S proteins in the prefusion conformation is described, which results in greatly increased expression, conformational homogeneity, and elicitation of potent antibody responses, and an engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. Expand
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
TLDR
A viral antigen is sought that provides greater protection than currently available vaccines and focused on antigenic site Ø, a metastable site specific to the prefusion state of the RSV fusion (F) glycoprotein, as this site is targeted by extremely potent RSV-neutralizing antibodies. Expand
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.
TLDR
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage; prospects of ending this pandemic rest on the development of effective interventions and the protection of current vaccines. Expand
The histopathology of fatal untreated human respiratory syncytial virus infection
TLDR
Airway obstruction was a prominent feature in all cases attributed to epithelial and inflammatory cell debris mixed with fibrin, mucus, and edema, and compounded by compression from hyperplastic lymphoid follicles, which inform the understanding of RSV pathogenesis and may facilitate the development of new approaches for prevention and treatment. Expand
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
TLDR
There is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards. Expand
...
1
2
3
4
5
...